Genmab A/S (GEN) DKK1
Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in various phases, including Ofatumumab for the treatment of, among others, Waldenstrom’s Macroglobulinemia and chronic lymphocytic leukemia; Daratumumab, for the treatment of multiple myeloma; Teprotumumab, aimed at active thyroid eye disease, and HuMax-TF-ADC for the treatment of solid cancers, among others. Additionally, the Company has more than ten product candidates in pre-clinical phase. It develops its projects under worldwide co-development and commercialization agreements with GlaxoSmithKline, H. Lundbeck A/S, Roche, and Seattle Genetics, among others. It has three wholly owned subsidiaries in the Netherlands and the United States.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.